Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

joint with the meeting on Antibodies as Drugs (X2)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel


March 6—10, 2016

Fairmont Chateau Whistler, Whistler, British Columbia, Canada


Sponsored by Regeneron Pharmaceuticals, Inc.


BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

** Meeting has ended **

Discounted Abstract Deadline: November 5, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time

Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is December 8, 2015)

Global Health Travel Award Deadline:

*All deadlines end at 11:59 PM US Mountain Standard Time


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: November 5, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: December 8, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:

  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is November 5, 2015)

Discounted Registration Deadline: January 7, 2016

*All deadlines end at 11:59 PM US Mountain Standard Time


Registration Fee: 845.00 USD* (includes 150.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 995.00 USD*
Student Registration Fee: 770.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that some meeting participants have received calls and emails from a number of different housing services, including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a lodging reservation with them.

We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.

Meeting Summary



The past decade has seen tremendous developments in novel cancer therapies, through targeting of tumor cell-intrinsic pathways whose activity is linked to genetic alterations, as well as the targeting of tumor cell-extrinsic factors such as growth factors. Remarkable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies, possibly due to the lack of T cell repertoire with specificity against cancer antigens. This creates the need for effective means of expanding the T cells in patients via immunization, i.e., cancer vaccines. Much progress has been made in recent years in this regard, and several phase III clinical trials testing various approaches to therapeutic vaccination are ongoing. The challenge for next-generation vaccines is to resolve the discrepancy between the immune and clinical efficacy measured by the rate of cancer rejection. The future immunotherapy of cancer lies in combination approaches targeting T cells as well as cancer genes to combat underlying inflammation. Spectacular progress has been made in these two parallel fields, i.e., cancer genomics and genetics, and tumor immunology. It is time now to link these fields to enable the linking of genetic alterations with the type of immune response. The meeting will therefore host cancer geneticists, cancer biologists, experts in cancer antigen presentation, tumor immunologists and vaccinologists. It will discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigen presentation and T cell biology might enable development of next-generation curative therapies for patients with cancer.